Growing Artificial Organs With Help From Machine Learning
Researchers from the Moscow Institute of Physics and Technology, Ivannikov Institute for System Programming, and the Harvard Medical School-affiliated Schepens Eye Research Institute have developed a neural network capable of recognizing retinal tissues during the process of their differentiation in a dish. Unlike humans, the algorithm achieves this without the need to modify cells, making the method suitable for growing retinal tissue for developing cell replacement therapies to treat blindness and conducting research into new drugs.
Credit: MIPT Press Office
Researchers from the Moscow Institute of Physics and Technology, Ivannikov Institute for System Programming, and the Harvard Medical School-affiliated Schepens Eye Research Institute have developed a neural network capable of recognizing retinal tissues during the process of their differentiation in a dish. Unlike humans, the algorithm achieves this without the need to modify cells, making the method suitable for growing retinal tissue for developing cell replacement therapies to treat blindness and conducting research into new drugs. The study was published in Frontiers in Cellular Neuroscience.
This would allow to expand the applications of the technology for multiple fields including the drug discovery and development of cell replacement therapies to treat blindness
In multicellular organisms, the cells making up different organs and tissues are not the same. They have distinct functions and properties, acquired in the course of development. They start out the same, as so-called stem cells, which have the potential to become any kind of cell the mature organism incorporates. They then undergo differentiation by producing proteins specific to certain tissues and organs.
The most advanced technique for replicating tissue differentiation in vitro relies on 3D cell aggregates called organoids. The method has already proved effective for studying the development of the retina, the brain, the inner ear, the intestine, the pancreas, and many other tissue types. Since organoid-based differentiation closely mimics natural processes, the resulting tissue is very similar to the one in an actual biological organ.
Some of the stages in cell differentiation toward retina have a stochastic (random) nature, leading to considerable variations in the number of cells with a particular function even between artificial organs in the same batch. The discrepancy is even greater when different cell lines are involved. As a result, it is necessary to have a means of determining which cells have already differentiated at a given point in time. Otherwise, experiments will not be truly replicable, making clinical applications less reliable, too.
To spot differentiated cells, tissue engineers use fluorescent proteins. By inserting the gene responsible for the production of such a protein into the DNAof cells, researchers ensure that it is synthesized and produces a signal once a certain stage in cell development has been reached. While this technique is highly sensitive, specific, and convenient for quantitative assessments, it is not suitable for cells intended for transplantation or hereditary disease modeling.
To address that pitfall, the authors of the recent study in Frontiers in Cellular Neuroscience have proposed an alternative approach based on tissue structure. No reliable and objective criteria for predicting the quality of differentiated cells have been formulated so far. The researchers proposed that the best retinal tissues — those most suitable for transplantation, drug screening, or disease modeling — should be selected using neural networks and artificial intelligence.
“One of the main focuses of our lab is applying the methods of bioinformatics, machine learning, and AI to practical tasks in genetics and molecular biology. And this solution, too, is at the interface between sciences. In it, neural networks, which are among the things MIPT traditionally excels at, address a problem important for biomedicine: predicting stem cell differentiation into retina,” said study co-author Pavel Volchkov, who heads the Genome Engineering Lab at MIPT.
“The human retina has a very limited capacity for regeneration,” the geneticist went on. “This means that any progressive loss of neurons — for example, in glaucoma — inevitably leads to complete loss of vision. And there is nothing a physician can recommend, short of getting a head start on learning Braille. Our research takes biomedicine a step closer to creating a cellular therapy for retinal diseases that would not only halt the progression but reverse vision loss.”